AI-generated summary
The authors studied LNCaP prostate cancer cells in the laboratory to test whether combining cisplatin with low-level laser treatment affects cell viability. They report that the combination reduced cell viability and increased lipid peroxidation and LDH activity, and they describe it as promising. The study was conducted on a cell line rather than in people.
- Who or what was studied
- LNCaP prostate cancer cell line (cultured cells)
- Limits stated in the abstract
- The study used cultured cancer cells only, so the results cannot be directly applied to patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Light-emitting diode. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.